Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis

Abstract

Renal amyloidosis is a complication of ankylosing spondylitis. A possible pathogenetic role is due to TNF-α, with a direct action on glomerular receptors TNFR2 and renal injury, secondary to deposition of amyloid fibrils. The most frequent clinical manifestation is proteinuria or nephrotic syndrome. Etanercept, a soluble receptor of TNF-α, binds this circulant cytokine with a progressive improvement of renal function and reduction of deposits of amyloid. Transient leukopenia, observed during ankylosing spondylitis, should not be considered a controindication to the use of Etanercept, but it requires a constant monitoring. The benefit observed in our patient can represent an indication to the use of Etanercept for the management of amyloidosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Info
Issue
Section
Case Reports
Statistics
  • Abstract views: 744

  • PDF: 891
How to Cite
Bellissimo, S., Ferrucci, M., Gallo, A., & Stisi, S. (1). Response to anti-TNF-α treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis. Reumatismo, 59(3), 240-243. https://doi.org/10.4081/reumatismo.2007.240

Most read articles by the same author(s)

1 2 > >>